| Theme |
Testify the concepts of renal osteodystrophy and chronic kidney disease-bone and mineral disorder (CKD-MBD) |
| Title |
Recent development of phosphate-lowering drugs for chronic kidney disease patients |
| Author |
Takashi Akiba |
Department of Blood Purification, Kidney Center, Tokyo Women's Medical University |
| [ Summary ] |
Hyperphosphatemia is a very important cause of mineral and bone abnormality in chronic kidney disease (CKD), Therefore the prevention of hyperphosphatemia may reduce overall risk and cardiac deaths in CKD patients.
An increase of the dialysis dose and dietary phosphorus restriction are the goals of therapy, but results from these methods are difficult to achieve. Therefore, the development of phosphorus–lowering drugs is desirable. We discuss anion exchange resins, metal-containing phosphate lowering drugs, and drugs other than phosphate binders. These have not been very effective in controlling serum phosphate levels in the range of values recommended by guidelines. Further development of new drugs is therefore necessary. |